STOCK TITAN

Spyre Therapeutics SEC Filings

SYRE NASDAQ

Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Investors trying to untangle Spyre Therapeutics’ biotech disclosures often wade through pages of immunology jargon, multi-year R&D accruals, and milestone-based licensing clauses. Locating clinical-trial costs in a 10-K or confirming a sudden Form 8-K study halt can take hours, and tracking executive share sales before financing rounds is even harder. That complexity is why so many searches start with natural questions like “where can I find Spyre Therapeutics quarterly earnings report 10-Q filing?” or “Spyre Therapeutics insider trading Form 4 transactions.” We built this page to answer those questions immediately.

With Stock Titan’s AI-powered analysis, every Spyre Therapeutics SEC filing is explained simply. Our algorithms parse the latest 10-K annual report, highlight key pipeline disclosures, and surface cash-burn trends, giving you a “Spyre Therapeutics annual report 10-K simplified” view in seconds. Real-time alerts flag “Spyre Therapeutics Form 4 insider transactions” the moment they hit EDGAR, while concise summaries break down each “Spyre Therapeutics 8-K material events explained” notice. Whether you need “Spyre Therapeutics proxy statement executive compensation” tables, or an “earnings report filing analysis” of quarterly R&D spend, the information arrives ready to use.

Every filing is linked to what matters for this clinical-stage IBD innovator. Compare α4β7 antibody trial results across quarters, monitor financing covenants that could shift run-way projections, or study “understanding Spyre Therapeutics SEC documents with AI” case notes that connect pipeline milestones to market valuation. Our coverage spans all forms—10-K, 10-Q, 8-K, S-1, and the executive stock transactions Form 4 feed—updated in real time. Spend less time decoding dense biology and more time making informed decisions with complete, investor-ready context.

Rhea-AI Summary

The Vanguard Group filed Amendment No. 15 to Schedule 13G on Summit Hotel Properties (INN) covering holdings as of 30 Jun 2025.

  • Beneficial ownership: 13,178,484 common shares, equal to 11.74 % of shares outstanding.
  • Voting power: 0 sole; 69,079 shared—Vanguard exercises very limited voting authority.
  • Dispositive power: 13,006,838 sole; 171,646 shared.
  • Filed under Rule 13d-1(b) as an investment adviser (IA); securities held in the ordinary course for client accounts.
  • Certification signed by Ashley Grim, Head of Global Fund Administration, on 29 Jul 2025.

The filing confirms Vanguard remains a major passive holder of INN. While the 11.74 % stake provides market influence, the near-zero voting power limits its ability to sway corporate governance directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Spyre Therapeutics (SYRE)?

The current stock price of Spyre Therapeutics (SYRE) is $16.97 as of July 31, 2025.

What is the market cap of Spyre Therapeutics (SYRE)?

The market cap of Spyre Therapeutics (SYRE) is approximately 1.0B.

What is the core focus of Spyre Therapeutics?

Spyre Therapeutics is a clinical-stage biotechnology company that focuses on developing innovative therapies for inflammatory bowel disease (IBD) and other immune-mediated disorders using advanced antibody engineering and precision medicine approaches.

How does Spyre Therapeutics design its therapies?

The company leverages state-of-the-art antibody engineering, rational therapeutic combinations, and precision medicine techniques to create extended half-life monoclonal antibodies, targeting key molecules involved in IBD pathology.

What are the key targets in Spyre Therapeutics’ pipeline?

Spyre’s pipeline includes investigational therapies targeting the integrin α4β7, the cytokine TL1A, and the p19 subunit of IL-23, which are critical to modulating immune responses in IBD.

How does the technology platform of Spyre Therapeutics differ from traditional therapies?

Spyre utilizes extended half-life technologies and precision medicine to design therapies that potentially reduce dosing frequency while maintaining high efficacy, offering a distinct advantage over traditional treatments.

What role does precision medicine play in Spyre’s strategy?

Precision medicine is central to Spyre’s approach, enabling the company to tailor treatments based on individual patient profiles, ultimately optimizing efficacy and minimizing side effects.

In which market segments does Spyre Therapeutics operate?

Spyre operates in the clinical-stage biotechnology sector with a focus on developing biopharmaceutical therapies for inflammatory bowel disease and other immune-mediated conditions, targeting both monotherapy and combination therapy markets.

How does Spyre differentiate its therapeutic approach?

Spyre differentiates itself through its combination of advanced antibody engineering, rational therapeutic design, and precision patient selection, which together aim to offer innovative and convenient treatment options.
Spyre Therapeutics

NASDAQ:SYRE

SYRE Rankings

SYRE Stock Data

1.01B
52.78M
8.72%
101.11%
16.63%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM